Vistagen Therapeutics, Inc. (VTGN)
NASDAQ: VTGN · Real-Time Price · USD
4.330
+0.050 (1.17%)
At close: Dec 5, 2025, 4:00 PM EST
4.380
+0.050 (1.15%)
After-hours: Dec 5, 2025, 7:48 PM EST
Vistagen Therapeutics Income Statement
Financials in millions USD. Fiscal year is April - March.
Millions USD. Fiscal year is Apr - Mar.
| TTM
| FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
| Sep '25 Sep 30, 2025 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 |
| Revenue | 0.72 | 0.49 | 1.06 | -0.23 | 1.11 | 1.09 | |
| Revenue Growth (YoY) | -17.69% | -54.32% | - | - | 1.78% | - | |
| Gross Profit | 0.72 | 0.49 | 1.06 | -0.23 | 1.11 | 1.09 | |
| Selling, General & Admin | 16.99 | 17.08 | 14.06 | 14.66 | 13.96 | 7.64 | |
| Research & Development | 49.21 | 39.38 | 20.02 | 44.38 | 34.92 | 11.38 | |
| Operating Expenses | 66.19 | 56.46 | 34.09 | 59.04 | 48.89 | 19.02 | |
| Operating Income | -65.47 | -55.97 | -33.02 | -59.27 | -47.78 | -17.93 | |
| Interest Expense | - | - | - | - | - | -0.01 | |
| Interest & Investment Income | 3.23 | 4.56 | 3.35 | 0.03 | 0.02 | 0.02 | |
| Other Non Operating Income (Expenses) | 0.01 | 0.01 | 0.31 | - | - | 0 | |
| EBT Excluding Unusual Items | -62.24 | -51.41 | -29.36 | -59.24 | -47.76 | -17.93 | |
| Pretax Income | -62.24 | -51.41 | -29.36 | -59.24 | -47.76 | -17.93 | |
| Income Tax Expense | - | 0.01 | 0 | 0.01 | 0 | 0 | |
| Net Income | -62.24 | -51.42 | -29.36 | -59.25 | -47.76 | -17.93 | |
| Preferred Dividends & Other Adjustments | - | - | - | - | 0.95 | 24.39 | |
| Net Income to Common | -62.24 | -51.42 | -29.36 | -59.25 | -48.71 | -42.32 | |
| Shares Outstanding (Basic) | 32 | 31 | 19 | 7 | 7 | 3 | |
| Shares Outstanding (Diluted) | 32 | 31 | 19 | 7 | 7 | 3 | |
| Shares Change (YoY) | 7.22% | 59.53% | 178.13% | 5.45% | 129.85% | 96.34% | |
| EPS (Basic) | -1.92 | -1.67 | -1.52 | -8.51 | -7.38 | -14.74 | |
| EPS (Diluted) | -1.92 | -1.67 | -1.52 | -8.51 | -7.38 | -14.74 | |
| Free Cash Flow | -53.16 | -42.29 | -25.87 | -49.93 | -45.46 | -12.35 | |
| Free Cash Flow Per Share | -1.64 | -1.37 | -1.34 | -7.17 | -6.89 | -4.30 | |
| Gross Margin | 100.00% | 100.00% | 100.00% | - | 100.00% | 100.00% | |
| Operating Margin | -9080.86% | -11517.08% | -3103.48% | - | -4308.68% | -1646.06% | |
| Profit Margin | -8631.90% | -10579.83% | -2759.59% | - | -4392.42% | -3884.33% | |
| Free Cash Flow Margin | -7373.09% | -8701.24% | -2431.77% | - | -4099.28% | -1133.45% | |
| EBITDA | -65.3 | -55.82 | -32.89 | -59.14 | -47.63 | -17.82 | |
| D&A For EBITDA | 0.17 | 0.15 | 0.13 | 0.13 | 0.15 | 0.12 | |
| EBIT | -65.47 | -55.97 | -33.02 | -59.27 | -47.78 | -17.93 | |
| Revenue as Reported | 0.72 | 0.49 | 1.06 | -0.23 | 1.11 | 1.09 | |
Source: S&P Capital IQ. Standard template.
Financial Sources.